8-K: Humana Reaffirms FY 2025 Earnings Guidance Ahead of Investor Meetings

Humana Inc. announced it will reaffirm its full-year 2025 diluted and adjusted earnings per share guidance during upcoming investor and analyst meetings.

Summary

• Humana Inc. (the Company) senior management is scheduled to meet with investors and analysts between June 2, 2025, and June 30, 2025.
• During these meetings, the Company intends to reaffirm its guidance for the year ending December 31, 2025 (FY 2025).
• The reaffirmed guidance includes approximately $14.68 in diluted earnings per common share (EPS) and approximately $16.25 in adjusted earnings per common share (Adjusted EPS).
• This guidance is consistent with the guidance previously issued in the Company's press release dated April 30, 2025.
• Humana will also host an Investor Conference for analysts and institutional investors on Monday, June 16, 2025, at 2:00 p.m. EST, accessible via live-stream on the Company's Investor Relations page.
• The Investor Conference will feature presentations from Humana leaders on strategic direction, operational and financial progress, and future performance expectations.
• Adjusted EPS is a non-GAAP financial measure, which management believes provides a comprehensive perspective for comparing and analyzing core operating performance over time, and is used for planning, decision-making, and incentive compensation.
• A reconciliation of GAAP EPS to Adjusted EPS for FY 2025 guidance includes adjustments for amortization of identifiable intangibles ($0.49), put/call valuation adjustments associated with non-consolidating minority interest investments ($1.35), value creation initiatives ($0.20), and cumulative net tax impact (-$0.47).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the company is reaffirming its previously issued guidance, suggesting stability and confidence in its financial outlook. There are no negative surprises or changes to the guidance.

Positives

• Reaffirmation of full-year 2025 earnings guidance provides stability and predictability for investors.
• The Company's commitment to transparency through scheduled investor meetings and an Investor Conference.

Risks

• Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, as detailed in the Company's SEC filings Risk Factors section.

Future Outlook

Humana intends to reaffirm its full-year 2025 diluted EPS guidance of approximately $14.68 and adjusted EPS guidance of approximately $16.25. The company will also host an Investor Conference on June 16, 2025, to discuss strategic direction, operational and financial progress, and future performance expectations.

Management Comments

• "Members of Humana Inc.'s senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025."
• "During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share (EPS) or approximately $16.25 in adjusted earnings per common share (Adjusted EPS), in each case for the year ending December 31, 2025 (FY 2025)."
• "This guidance is consistent with the guidance issued in the Company's press release dated April 30, 2025."
• "Management believes that this measure [Adjusted EPS], when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time."
• "Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation."

Industry Context

This announcement is specific to Humana's internal financial guidance and investor relations activities. As a major player in the U.S. healthcare insurance sector, Humana's reaffirmed guidance provides an update on its expected financial health within the broader industry, which is subject to evolving regulatory landscapes, healthcare costs, and competitive pressures.

Comparison to Industry Standards

• The document does not provide specific comparable company or project data to assess Humana's results against global benchmarks. It focuses solely on Humana's reaffirmed internal guidance.

Stakeholder Impact

• Shareholders and potential investors: Provides updated and reaffirmed financial guidance, aiding investment decisions.
• Analysts: Offers clarity on the company's financial outlook and upcoming opportunities for engagement.
• Management: Reaffirms targets used for planning, decision-making, and incentive compensation.

Next Steps

• Humana senior management to meet with investors and analysts between June 2, 2025, and June 30, 2025.
• Humana to host an Investor Conference on Monday, June 16, 2025, at 2:00 p.m. EST.
• Replay of the Investor Conference will be available in the Historical Webcasts and Presentations section of the Investor Relations page.

Key Dates

Recommendation

Keywords

Humana, earnings guidance, EPS, Adjusted EPS, investor relations, healthcare, insurance, financial performance, SEC filing, Regulation FD